General Proximity · May 2026
General Proximity announced strategic investment from FreeMind Investments and Daewoong Pharmaceutical; amount not disclosed.
The next generation of induced-proximity medicines.
Company research
Public company, workplace, funding, and market signals
Updated Aug 16, 2026
Overview
General Proximity is a San Francisco biotech company developing next-generation induced-proximity medicines using its proprietary OmniTAC platform to discover effector-target pairs for previously hard-to-drug targets.
Primary product
OmniTAC platform for induced-proximity drug discovery and development
Founded
2019
Headquarters
San Francisco, California, United States
Team size
11-50
Industry
Biotechnology
Sub-industry
Drug discovery / induced-proximity therapeutics
Business model
platform biotech
drug discovery partnerships
preclinical pipeline development
Funding
People & investors
Founders
Founder and CEO
Investors
AbbVie
age1
Alec Nielsen
ARPA-H
Astellas
Ben Mann
Bristol Myers Squibb
Daewoong Pharmaceutical Co., Ltd.
Daiichi Sankyo
De Thompson V
Felicis
FreeMind Investments
Jeff Dean
Jim Dahl
Juan Benet
Modi Ventures
National Cancer Institute
Nish Bhat
Ono Pharmaceutical
Servier
Trevor Martin
Uri Lopatin
Wilson Sonsini
Y Combinator
Work & culture
Public posts emphasize hiring, high talent density, and a mission-driven science culture focused on induced proximity medicines. Public detail on day-to-day culture is limited.
Compensation
No public salary bands or compensation policy found in primary sources.
Benefits
Locale
Function Health
other benefits mentioned in a LinkedIn post; details not fully public
Product & market
Pricing
Primarily partnership/licensing and preclinical collaboration revenue; not publicly disclosed in detail.
Differentiators
- —Mechanism-agnostic proximity discovery engine
- —Effectome-scanning approach
- —OmniTAC platform
- —Focused on previously undruggable targets
- —Combination of internal pipeline plus strategic pharma collaborations
Technology
PCR
Python
Matlab
LinkedIn
Medium
Customers
Daiichi Sankyo
AbbVie
Servier
Astellas
Ono Pharmaceutical
Bristol-Myers Squibb
Competitors
Arvinas
Kymera Therapeutics
C4 Therapeutics
Lycia Therapeutics
Monte Rosa Therapeutics
Scale & contact
Estimated monthly visits
4.2K
Traffic estimate as of Jun 2026
Latest news
Dealroom · Mar 2026
Reported the oversubscribed pre-Series A round and noted total capital raised above $20M including grants.
Pharmaceutical Technology · Nov 2025
Third-party coverage of the Daiichi Sankyo collaboration and the company’s focus on induced-proximity oncology programs.
General Proximity · Nov 2025
General Proximity announced a strategic multi-target collaboration with Daiichi Sankyo through its Boston research institute to apply OmniTAC to oncology programs.
General Proximity · Jan 2025
The company came out of stealth, announced $16M raised, and described its OmniTAC platform and initial target areas.
Jobs and careers at General Proximity
8 jobs at General Proximity
Scientist/Sr. Scientist, DMPK
On-site
Chemistry Team
San Francisco, CA
1mo ago
On-site
Full-time
Scientist/Sr. Scientist, Computational Chemistry
On-site
Chemistry Team
San Francisco, CA
1mo ago
On-site
Full-time
Scientist, Medicinal Chemistry
On-site
Chemistry Team
San Francisco, CA
3mo ago
On-site
Full-time
Scientist, Mechanistic Biology
On-site
Discovery Biology
San Francisco, CA
3mo ago
On-site
Full-time
Scientist II/Senior Scientist, Medicinal Chemistry
On-site
Chemistry Team
San Francisco, CA
4mo ago
On-site
Full-time
Lab Technician/Operations Manager (Contract)
On-site
Operations
San Francisco, CA
7mo ago
On-site
Full-time
Scientist/Sr. Scientist, Chemical Biology
On-site
Chemistry Team
San Francisco, CA
9mo ago
On-site
Full-time
Other Positions
On-site
San Francisco, CA
9mo ago
On-site
Full-time